Opus Genetics Statistics
Total Valuation
Opus Genetics has a market cap or net worth of $381.36 million. The enterprise value is $337.40 million.
Important Dates
The next estimated earnings date is Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Opus Genetics has 71.15 million shares outstanding. The number of shares has increased by 132.91% in one year.
| Current Share Class | 71.15M |
| Shares Outstanding | 71.15M |
| Shares Change (YoY) | +132.91% |
| Shares Change (QoQ) | +14.08% |
| Owned by Insiders (%) | 14.80% |
| Owned by Institutions (%) | 32.56% |
| Float | 34.82M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.86 |
| Forward PS | 23.79 |
| PB Ratio | 24.41 |
| P/TBV Ratio | 24.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 23.77 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.43, with a Debt / Equity ratio of 0.07.
| Current Ratio | 6.43 |
| Quick Ratio | 6.20 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.33 |
Financial Efficiency
Return on equity (ROE) is -242.41% and return on invested capital (ROIC) is -114.76%.
| Return on Equity (ROE) | -242.41% |
| Return on Assets (ROA) | -55.39% |
| Return on Invested Capital (ROIC) | -114.76% |
| Return on Capital Employed (ROCE) | -90.90% |
| Weighted Average Cost of Capital (WACC) | 7.41% |
| Revenue Per Employee | $507,000 |
| Profits Per Employee | -$1.77M |
| Employee Count | 28 |
| Asset Turnover | 0.33 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +605.26% in the last 52 weeks. The beta is 0.52, so Opus Genetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.52 |
| 52-Week Price Change | +605.26% |
| 50-Day Moving Average | 4.10 |
| 200-Day Moving Average | 2.30 |
| Relative Strength Index (RSI) | 65.79 |
| Average Volume (20 Days) | 718,548 |
Short Selling Information
The latest short interest is 2.01 million, so 2.83% of the outstanding shares have been sold short.
| Short Interest | 2.01M |
| Short Previous Month | 1.11M |
| Short % of Shares Out | 2.83% |
| Short % of Float | 5.78% |
| Short Ratio (days to cover) | 1.77 |
Income Statement
In the last 12 months, Opus Genetics had revenue of $14.20 million and -$49.59 million in losses. Loss per share was -$0.80.
| Revenue | 14.20M |
| Gross Profit | -16.62M |
| Operating Income | -38.60M |
| Pretax Income | -49.59M |
| Net Income | -49.59M |
| EBITDA | -38.55M |
| EBIT | -38.60M |
| Loss Per Share | -$0.80 |
Full Income StatementBalance Sheet
The company has $45.09 million in cash and $1.13 million in debt, with a net cash position of $43.96 million or $0.62 per share.
| Cash & Cash Equivalents | 45.09M |
| Total Debt | 1.13M |
| Net Cash | 43.96M |
| Net Cash Per Share | $0.62 |
| Equity (Book Value) | 15.35M |
| Book Value Per Share | 0.22 |
| Working Capital | 42.26M |
Full Balance SheetCash Flow
| Operating Cash Flow | -35.25M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 53,000 |
| Net Borrowing | 1.00M |
| Free Cash Flow | -35.25M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | -117.05% |
| Operating Margin | -271.90% |
| Pretax Margin | -349.33% |
| Profit Margin | n/a |
| EBITDA Margin | -271.53% |
| EBIT Margin | -271.90% |
| FCF Margin | n/a |
Dividends & Yields
Opus Genetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -132.91% |
| Shareholder Yield | -132.91% |
| Earnings Yield | -13.00% |
| FCF Yield | -9.24% |
Analyst Forecast
The average price target for Opus Genetics is $9.67, which is 80.41% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.67 |
| Price Target Difference | 80.41% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 109.63% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Opus Genetics has an Altman Z-Score of -5.2 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.2 |
| Piotroski F-Score | 4 |
